Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 9Lymphoma, Large B-Cell, Diffuse 8Breast Neoplasms 8Lymphoma, Follicular 6Neoplasms 5Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Endometrial Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Hodgkin Disease 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4fludarabine phosphate 4Trabectedin 4Radiotherapy 4Phantoms, Imaging 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Ewing × copanlisib × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡